Biomimedica closes $11.9M Series B round; Are Massachusetts medical device jobs declining?;

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

> Biomimedica has closed its $11.9M Series B round. The company is developing synthetic cartilage replacement implants. Release

> Wright Medical Group ($WMGI) is launching a patient outreach program to increase awareness of hammertoe treatment options. The company makes a hammertoe implant. Release

> The FDA has issued draft guidance designed to lower the risk category for blood access devices used in hemodialysis. Story

> Aeris Therapeutics says a recent clinical trial has shown that its AeriSeal system helped improve lung function for advanced emphysema patients for up to one year following treatment. Release

> While the recent Battelle/BIO State Bioscience Industry development report showed that life sciences jobs have grown in the U.S. overall, medical device jobs in Massachusetts--one of the main industry clusters in the country--appear to have dipped. Story

Biotech News

 @FierceBiotech: Check out the Fierce team's BIO 2012 convention slideshow featuring the faces of biotech leaders. More | Follow @FierceBiotech

 @JohnCFierce: Benefits of scientific understanding exceed fears of Crichton-style weaponized bird flu fears. More | Follow @JohnCFierce

> Guarding Humira treasure, Abbott mounts a challenge to biosimilars. Story

> Scientists demonstrate how bird flu could trigger a pandemic. Article

> FDA tracks rising impact of the 'placebo effect' in antipsychotic trials. Story

Pharma News

 @FiercePharma: If the Supreme Court of the United States doesn't strike down biosimilars with the rest of health reform, Abbott aims to stop them. More | Follow @FiercePharma

> Roche overlooks 80,000 adverse reaction complaints. Story

> FDA delivers Xarelto bad news to J&J, Bayer. News

> Abbott stands alone in challenge to biosimilars law. Article

And Finally... A New England Journal of Medicine "perspective" article charges the FDA with ordering a flawed post-marketing studies initiative for metal-on-metal hip implants, arguing that the new studies have been slow to start and are hampered by methodology issues. Story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.